Eliem Therapeutics, Inc. (ELYM)

3.8700 +0.0200 (+0.52%) At close: 04:00PM EDT

Eliem Therapeutics, Inc.

23515 NE Novelty Hill Road
Suite B221 #125
Redmond, WA 98053
United States
877 354 3689
https://eliemtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 9

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Andrew Levin M.D., Ph.D.	Principal Financial Officer & Executive Chairman	73k	N/A	1978
Dr. Valerie Morisset Ph.D.	Chief Scientific Officer and Executive VP of Research & Development	617.87k	N/A	1970
Ms. Emily Pimblett	Principal Accounting Officer	N/A	N/A	1984
Ms. Jo Palmer-Phillips Ph.D.	Chief Development Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.

Corporate Governance

Eliem Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.